Table 2.

Investigator-assessed response utilizing RECIST (version: 1.1)

Best overall response	Anlotinib + oxaliplatin + capecitabine (n = 30)
CR, n (%)	1 (3.3)
PR, n (%)	22 (73.3)
SD, n (%)	5 (16.7)
PD, n (%)	1 (3.3)
NE, n (%)	1 (3.3)
ORRa, n (%, 95%CI)	23 (76.7,57.7–90.1)
DCRb, n (%, 95%CI)	28 (93.3, 77.9–99.2)

RECIST, Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; DCR, disease control rate; CI, confidence interval

^aORR was defined as the proportion of patients with a best overall tumor response, CR, or PR

^bDCR refers to the proportion of patients with response and stable disease